Stephanie N. Bass
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stephanie N. Bass has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jason R. Yerke
Cleveland Clinic
4 shared publications - Aanchal Kapoor
Cleveland Clinic
2 shared publications - Siddharth Dugar
Cleveland Clinic
2 shared publications - Tien Q. Pham
Department of Pharmacy, Cleveland Clinic, OH, USA
2 shared publications Ajit Moghekar
Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH
1 shared publication- Alyssa Y. Chen
Department of Pharmacy Cleveland Clinic Cleveland Ohio USA
1 shared publication
Latest Publications
- 12 November 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Molecular Adsorbent Recirculating System Therapy in Severe Amlodipine Overdose: Two Cases and Review of the Literature
Background: Calcium channel blocker (CCB) overdose is a significant cause of cardiovascular drug overdose-related mortality, with amlodipine emerging as the most frequently implicated agent in serious intoxication. Current management strategies for CCB poisoning include vasopressors, high-dose insulin therapy, and other adjunctive treatments. The unique pharmacodynamic profile of amlodipine can lead to severe and persistent vasoplegic shock that is refractory to conventional therapy. The Molecular Adsorbent Recirculating System (MARS), an albumin dialysis technique capable of removing protein-bound toxins, has been proposed as a potential adjunctive therapy in cases of refractory vasodilatory shock associated with severe amlodipine poisoning. Methods: We report two cases of severe amlodipine poisoning complicated by refractory vasodilatory shock treated with the Molecular Adsorbent Recirculating System (MARS). A targeted PubMed search was also performed to identify published reports of calcium channel blocker intoxication with severe shock treated with MARS. Only reports describing amlodipine ingestion, either alone or with co-ingested agents, were included. Results: Both cases involved severe amlodipine poisoning complicated by refractory vasodilatory shock with multiorgan dysfunction requiring multiple vasopressors, high-dose insulin therapy, mechanical ventilation, and renal replacement therapy. Initiation of MARS was temporally associated with progressive hemodynamic stabilization, including reductions in vasopressor requirements and improvement in lactate levels. In the first case, MARS was successfully continued during prone ventilation for severe acute respiratory distress syndrome. In the second case, persistent cardiopulmonary failure required extracorporeal membrane oxygenation (ECMO). Reinitiation of MARS during ECMO support was associated with improved lactate clearance and reduced vasopressor requirements. Conclusions: Severe amlodipine poisoning can result in profound and persistent vasodilatory shock with multiorgan dysfunction despite multiple conventional and adjunctive therapies. MARS may represent a useful adjunctive therapy in selected cases and can be integrated into complex critical care strategies, including prone ventilation and extracorporeal membrane oxygenation.
- 12 November 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Molecular Adsorbent Recirculating System Therapy in Severe Amlodipine Overdose: Two Cases and Review of the Literature
Background: Calcium channel blocker (CCB) overdose is a significant cause of cardiovascular drug overdose-related mortality, with amlodipine emerging as the most frequently implicated agent in serious intoxication. Current management strategies for CCB poisoning include vasopressors, high-dose insulin therapy, and other adjunctive treatments. The unique pharmacodynamic profile of amlodipine can lead to severe and persistent vasoplegic shock that is refractory to conventional therapy. The Molecular Adsorbent Recirculating System (MARS), an albumin dialysis technique capable of removing protein-bound toxins, has been proposed as a potential adjunctive therapy in cases of refractory vasodilatory shock associated with severe amlodipine poisoning. Methods: We report two cases of severe amlodipine poisoning complicated by refractory vasodilatory shock treated with the Molecular Adsorbent Recirculating System (MARS). A targeted PubMed search was also performed to identify published reports of calcium channel blocker intoxication with severe shock treated with MARS. Only reports describing amlodipine ingestion, either alone or with co-ingested agents, were included. Results: Both cases involved severe amlodipine poisoning complicated by refractory vasodilatory shock with multiorgan dysfunction requiring multiple vasopressors, high-dose insulin therapy, mechanical ventilation, and renal replacement therapy. Initiation of MARS was temporally associated with progressive hemodynamic stabilization, including reductions in vasopressor requirements and improvement in lactate levels. In the first case, MARS was successfully continued during prone ventilation for severe acute respiratory distress syndrome. In the second case, persistent cardiopulmonary failure required extracorporeal membrane oxygenation (ECMO). Reinitiation of MARS during ECMO support was associated with improved lactate clearance and reduced vasopressor requirements. Conclusions: Severe amlodipine poisoning can result in profound and persistent vasodilatory shock with multiorgan dysfunction despite multiple conventional and adjunctive therapies. MARS may represent a useful adjunctive therapy in selected cases and can be integrated into complex critical care strategies, including prone ventilation and extracorporeal membrane oxygenation.
- Open Access
- 27 August 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Impact of Duration of Intravenous Octreotide Infusion on Achieving Hemostasis in Patients With Acute Variceal Hemorrhage
Background: In acute variceal hemorrhage (AVH), guidelines recommend 2 to 5 days of octreotide following endoscopic hemostasis to reduce early rebleeding; however, the optimal duration of therapy remains undefined. Objective: To evaluate whether a shorter duration of octreotide therapy is non-inferior to a longer duration in preventing early rebleeding and adverse clinical outcomes. Methods: This multicenter, retrospective non-inferiority study included adults with cirrhosis and endoscopically confirmed AVH admitted to 13 hospitals within the Cleveland Clinic Health System between January 2020 and August 2024. Patients were categorized by post-endoscopic octreotide infusion duration: short-course (≤72 h) or long-course (>72 h). The primary outcome was 5-day rebleeding, with a prespecified non-inferiority margin of 15%. Secondary outcomes included 48-hour rebleeding, transfusion requirements, in-hospital mortality, adverse events, and octreotide-related costs. Results: Among 260 patients, 131 received short-course and 129 received long-course octreotide therapy. Rebleeding within 5 days occurred in 27.5% and 31.0% of patients, respectively (absolute risk difference = −3.5%; 95% confidence interval = −14.6% to 7.5%), meeting the non-inferiority threshold. Secondary outcomes were similar: 48-hour rebleeding (17.6% vs 20.2%), median blood transfusion (0 vs 0 units), and in-hospital mortality (10.7% vs 18.6%). Rates of bradycardia, hypo- or hyperglycemia, and ileus did not differ. Octreotide-related treatment costs were significantly lower in the short-course group. Conclusion and Relevance: In patients with AVH who achieved endoscopic hemostasis, short-course octreotide therapy was non-inferior to longer-course therapy in preventing early rebleeding, with similar clinical outcomes and lower treatment cost.
- 27 August 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Open AccessImpact of Duration of Intravenous Octreotide Infusion on Achieving Hemostasis in Patients With Acute Variceal Hemorrhage
Background: In acute variceal hemorrhage (AVH), guidelines recommend 2 to 5 days of octreotide following endoscopic hemostasis to reduce early rebleeding; however, the optimal duration of therapy remains undefined. Objective: To evaluate whether a shorter duration of octreotide therapy is non-inferior to a longer duration in preventing early rebleeding and adverse clinical outcomes. Methods: This multicenter, retrospective non-inferiority study included adults with cirrhosis and endoscopically confirmed AVH admitted to 13 hospitals within the Cleveland Clinic Health System between January 2020 and August 2024. Patients were categorized by post-endoscopic octreotide infusion duration: short-course (≤72 h) or long-course (>72 h). The primary outcome was 5-day rebleeding, with a prespecified non-inferiority margin of 15%. Secondary outcomes included 48-hour rebleeding, transfusion requirements, in-hospital mortality, adverse events, and octreotide-related costs. Results: Among 260 patients, 131 received short-course and 129 received long-course octreotide therapy. Rebleeding within 5 days occurred in 27.5% and 31.0% of patients, respectively (absolute risk difference = −3.5%; 95% confidence interval = −14.6% to 7.5%), meeting the non-inferiority threshold. Secondary outcomes were similar: 48-hour rebleeding (17.6% vs 20.2%), median blood transfusion (0 vs 0 units), and in-hospital mortality (10.7% vs 18.6%). Rates of bradycardia, hypo- or hyperglycemia, and ileus did not differ. Octreotide-related treatment costs were significantly lower in the short-course group. Conclusion and Relevance: In patients with AVH who achieved endoscopic hemostasis, short-course octreotide therapy was non-inferior to longer-course therapy in preventing early rebleeding, with similar clinical outcomes and lower treatment cost.
- 28 November 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (12) , 852-861
Terlipressin Administration Strategies in Hepatorenal Syndrome–Acute Kidney Injury: A Narrative Review of Continuous Infusion and Intermittent Bolus Approaches
Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of cirrhosis, marked by profound splanchnic vasodilation leading to renal hypoperfusion. Guidelines throughout the years have refined the definitions, classifications, and diagnostic criteria of HRS‐AKI to promote earlier recognition and intervention. Vasoconstrictor therapy remains the cornerstone of the management of HRS‐AKI. Among the available agents, terlipressin is the most well‐studied and has been endorsed by multiple international guidelines as first‐line therapy for HRS‐AKI. Although approved by the United States Food and Drug Administration for use in HRS‐AKI with an intermittent intravenous bolus dosing strategy, recent consensus guidance recommends continuous infusion as the preferred route of administration. This narrative review summarizes current evidence from clinical trials and comparative studies evaluating terlipressin continuous infusion versus intermittent bolus dosing strategies, with a focus on efficacy, safety, and operational considerations. Clinical trials comparing the two strategies have shown that the continuous infusion strategy provides comparable, and possibly superior, efficacy in HRS reversal compared to intermittent bolus dosing, while also demonstrating a lower incidence of adverse effects. Operational feasibility is supported by physical and chemical stability in various diluents over 24‐h infusion periods; however, implementation challenges remain, including limited line compatibility data and line access issues in patients with cirrhosis. In conclusion, the terlipressin continuous infusion strategy appears to be an efficacious, safe, and operationally plausible alternative to intermittent bolus dosing and may be considered for routine use in clinical practice.
- 28 November 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (12) , 852-861
Terlipressin Administration Strategies in Hepatorenal Syndrome–Acute Kidney Injury: A Narrative Review of Continuous Infusion and Intermittent Bolus Approaches
Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of cirrhosis, marked by profound splanchnic vasodilation leading to renal hypoperfusion. Guidelines throughout the years have refined the definitions, classifications, and diagnostic criteria of HRS‐AKI to promote earlier recognition and intervention. Vasoconstrictor therapy remains the cornerstone of the management of HRS‐AKI. Among the available agents, terlipressin is the most well‐studied and has been endorsed by multiple international guidelines as first‐line therapy for HRS‐AKI. Although approved by the United States Food and Drug Administration for use in HRS‐AKI with an intermittent intravenous bolus dosing strategy, recent consensus guidance recommends continuous infusion as the preferred route of administration. This narrative review summarizes current evidence from clinical trials and comparative studies evaluating terlipressin continuous infusion versus intermittent bolus dosing strategies, with a focus on efficacy, safety, and operational considerations. Clinical trials comparing the two strategies have shown that the continuous infusion strategy provides comparable, and possibly superior, efficacy in HRS reversal compared to intermittent bolus dosing, while also demonstrating a lower incidence of adverse effects. Operational feasibility is supported by physical and chemical stability in various diluents over 24‐h infusion periods; however, implementation challenges remain, including limited line compatibility data and line access issues in patients with cirrhosis. In conclusion, the terlipressin continuous infusion strategy appears to be an efficacious, safe, and operationally plausible alternative to intermittent bolus dosing and may be considered for routine use in clinical practice.